Development and Validation of a Prognostic Score Involving Disease Status, Patient Age and Donor Type for Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia

• Published in: Blood 2014-12, Vol.124 (21), p.1237-1237
• Main Authors: Michelis, Fotios V., Kotchetkov, Rouslan, Azeem, Aamir, Grunwald, Rebecca M., Uhm, Jieun, Alam, Naheed, Lambie, Anna, McGillis, Laura, Loach, David, Gupta, Vikas, Kuruvilla, John, Lipton, Jeffrey H., Kim, Dennis D., Seftel, Matthew D., Messner, Hans A.
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V124.21.1237.1237

Allogeneic hematopoietic cell transplantation (HCT) is a curative treatment option for acute myeloid leukemia (AML) when indicated. Numerous pre-transplant risk scores have been developed to predict post-transplant outcome, utilizing a variety of parameters. The purpose of this single-center study was to retrospectively develop and validate a prognostic score based on known significant pre-transplant variables for outcomes of 747 patients that underwent HCT for AML between 1978 and 2013. Median age of all patients at transplant was 44 years (range 17-71 years), 391 patients (52%) were female. HCT was performed in first complete remission (CR1) for 497 patients (67%) and in second complete remission (CR2) or advanced disease for 250 patients (33%). Donors were related for 538 patients (72%) and unrelated for 209 patients (28%). Peripheral blood stem cells (PBSC) were used as a graft source in 367 patients (49%). Myeloablative conditioning (MAC) was administered to 615 (82%) patients, 132 (18%) received reduced-intensity conditioning (RIC) regimens. HCT was performed over the time periods 1978-1990 (n=139), 1991-1999 (n=192), 2000-2006 (n=183) and 2007-2013 (n=233). Median follow-up of survivors was 90 months. Patients were assigned a combined score based on patient age, disease status and donor status. For disease status CR1, age